Press releases
LinKinVax has the trust of world-class partners and investors.
Our last Press releases
LinKinVax introduces its Scientific Advisory
Board with the appointment of three leading
experts in immunology and epidemiology
LinKinVax welcomes interim results of the ANRS
VRI06 Phase I trial evaluating a novel HIV vaccine
LinKinVax and Gustave Roussy collaborate to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer
LinKinvax just completed a new round of financing, initiated in 2022
Accelerating the production of more effective prophylactic or therapeutic vaccines and adapting them to emerging or rapidly mutating pathogens is a major public health challenge.
LinKinVax puts together a highly experienced team from the world of biopharmaceuticals to lead the clinical development and upscaling of its vaccine platform
LinKinVax appoints Dr Jiong Ma as independent board member
LinKinVax announces a collaboration with GTP Bioways for the development and production of its second-generation vaccine against SARS-CoV-2
LINKINVAX raises €4.350 million in funding
To accelerate the developpement of its innovative vaccine platform